Coherus Oncology, Inc. (CHRS) vs Jyong Biotech Ltd. Ordinary Shares (MENS)
Over the past year, CHRS outperformed MENS — -31.58% vs -95.66% annualized total return (price plus dividends).
A side-by-side comparison of Coherus Oncology, Inc. and Jyong Biotech Ltd. Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — CHRS vs MENS
growth of $100 · dividends reinvested · last 1yMetrics side by side
Did CHRS beat MENS?
Over the past year, CHRS outperformed MENS — -31.58% vs -95.66% annualized total return (price plus dividends).
Total return (annualized)
| Metric | CHRS | MENS |
|---|---|---|
| Total return (1Y) | -31.58% | -95.66% |
| Total return CAGR (3Y) | -31.40% | N/A |
| Total return CAGR (5Y) | -41.38% | N/A |
| Total return CAGR (10Y) | -26.92% | N/A |
MENS is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has CHRS beaten MENS?
- Over the past year, CHRS outperformed MENS — -31.58% vs -95.66% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.